Drugs / Quadrivalent seasonal influenza vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT05801978 | Apr 2023 → Sep 2027 expected | — | Emory University | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT06024096 Comparator | Sep 2023 → Dec 2024 | — | Emory University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quadrivalent seasonal influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05801978 ↗ |
| Known as | QIV | “In contrast, the quadrivalent influenza vaccine (QIV) generates an immunity that wanes quickly with no long-lasting protection.” NCT05801978 ↗ |
| Modality | Vaccine | “The FDA-approved quadrivalent seasonal influenza vaccine contains four distinct strains: two influenza A viruses and two influenza B viruses.” NCT06024096 ↗ |